Pyrazolo[4,3-c]isoquinolines as potential inhibitors of NF-kappaB activation

Biochem Pharmacol. 2010 May 15;79(10):1462-72. doi: 10.1016/j.bcp.2010.01.007. Epub 2010 Jan 21.

Abstract

In this work, we aimed to build a 3D-model of NIK and to study the binding of pyrazolo[4,3-c]isoquinolines with a view to highlight the structural elements responsible for their inhibitory potency. However, in the course of this work, we unexpectedly found that the pyrazolo[4,3-c]isoquinolines initially reported as NIK inhibitors were neither inhibitors of this enzyme nor of the alternative NF-kappaB pathway, but were in fact inhibitors of another kinase, the TGF-beta activated kinase 1 (TAK1) which is involved in the classical NF-kappaB pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arthritis, Rheumatoid / metabolism
  • HeLa Cells
  • Humans
  • Isoquinolines / antagonists & inhibitors*
  • MAP Kinase Kinase Kinases / drug effects
  • MAP Kinase Kinase Kinases / physiology
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / physiology
  • Pyrazoles / antagonists & inhibitors*
  • Recombinant Proteins
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Structure-Activity Relationship

Substances

  • Isoquinolines
  • NF-kappa B
  • Pyrazoles
  • Recombinant Proteins
  • MAP Kinase Kinase Kinases
  • MAP kinase kinase kinase 7